Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.38 |
| ▸ | CTSK | P43235 | 7/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1414251 | 1.00 | AAK1 (0.43) | AAK1ITGB3ITGA2BCTSKCTSS | |
| SCHEMBL25321261 | 0.90 | CTSK (0.42) | AAK1ITGB3ITGA2BCTSKCTSS | |
| SCHEMBL25321256 | 0.90 | CTSK (0.42) | AAK1ITGB3ITGA2BCTSKCTSS | |
| SCHEMBL28463725 | 0.86 | HDAC4 (0.46) | AAK1ITGB3ITGA2BCTSKCTSS | |
| SCHEMBL3120243 | 0.86 | AAK1 (0.43) | AAK1CTSKCTSSKMT2ACTSL | |
| SCHEMBL1414320 | 0.86 | HDAC4 (0.46) | AAK1ITGB3ITGA2BCTSKCTSS | |
| SCHEMBL1414317 | 0.86 | HDAC4 (0.46) | AAK1ITGB3ITGA2BCTSKCTSS | |
| SCHEMBL3117394 | 0.83 | AAK1 (0.44) | AAK1CTSKCTSSKMT2ACTSL | |
| SCHEMBL3125731 | 0.80 | AAK1 (0.39) | AAK1CTSKCTSSKMT2ACTSL | |
| SCHEMBL19355209 | 0.78 | CYP1A2 (0.40) | AAK1CTSKKMT2ACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436006-B2 | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSSEN PHARMACEUTICA N.V. (BE) | 2013-05-07 | — | — | US | disclosed |
| US-8426429-B2 | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSSEN PHARMACEUTICA N.V. (BE) | 2013-04-23 | — | — | US | disclosed |
| US-8383637-B2 | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSSEN PHARMACEUTICA N.V. (BE) | 2013-02-26 | — | — | US | disclosed |
| EP-1776349-B1 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-06 | — | — | EP | disclosed |
| EP-1789398-A1 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF B-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-30 | — | — | EP | disclosed |
| EP-1776349-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-25 | — | — | EP | disclosed |
| EP-1776350-A1 | NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF ß-SECRETASE ( BACE ) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-25 | — | — | EP | disclosed |
| US-20060178383-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-10 | — | — | US | disclosed |
| US-20060079686-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2006-04-13 | — | — | US | disclosed |
| US-20060079687-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-13 | — | — | US | disclosed |
| WO-2006024932-A1 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF B-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006017844-A1 | NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006017836-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178383-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | BACE2, BACE1, APP | AAK1 275/4885ITGB3 4149/4885ITGA2B 4243/4885 |
| US-20060079687-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | BACE2, BACE1, APP | AAK1 275/4885ITGB3 4149/4885ITGA2B 4243/4885 |
| US-20060079686-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | BACE2, BACE1, APP | AAK1 275/4885ITGB3 4149/4885ITGA2B 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.